Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF™ 1 - a randomised, Phase II study.
Christopher H GossIsabelle FajacRaksha JainWolfgang SeiboldAbhya GuptaMing-Chi HsuSivagurunathan SutharsanJane C DaviesMarcus Alexander MallPublished in: The European respiratory journal (2021)
BI 1265162 was safe, but did not demonstrate a potential for clinical benefit. Development has been terminated.